about
Adoptive cell therapies for glioblastomaMRP3: a molecular target for human glioblastoma multiforme immunotherapy.Advances in treatment of pediatric brain tumorsNovel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro.Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human gliomaRadioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMolecular targeted α-particle therapy for oncologic applications.State of the art chemotherapeutic management of pediatric brain tumors.Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.Cell therapies for glioblastoma.Novel therapies for meningiomas.Emerging monoclonal antibody therapies for malignant gliomas.Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapyImmunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas.A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.In vivo brain electrophoresis - a novel method for chemotherapy of CNS diseases.Immunotoxin therapy of cancer
P2860
Q27030863-868405B6-F369-484C-851A-4A8C38204F83Q30988770-24064853-CC37-4EFD-9340-F4986CD570A2Q33237311-E5EF3B13-8F08-4E33-8E03-A2A066C9B9ADQ33888876-9E8DAD5B-51D2-4356-A3F9-A0EE9E0CA616Q34657329-9181A5DC-3CF4-430E-880E-ACBBCAC275CAQ35659088-BAEA2A60-C66B-4195-ACC6-1D9C5471941DQ35814989-A1B51A71-B458-493E-B482-5A8CB6CEEAC0Q36492376-70B8B1CC-C320-4E2D-B0E4-7BA7C93BF220Q36499222-577BFEEC-A7B6-48EC-B341-D5700E3005A9Q36541937-DE4D44D7-704E-472B-8501-428C1EF4A37DQ36641500-3484B7B6-31A4-41E8-9F69-5C676441E278Q36764016-EDF4AD32-EFF2-4941-BFD8-841B1D759A5DQ37154421-E8645501-F258-429A-AFF1-715719665C56Q37159509-4F7269CD-92F0-4472-81FB-7BC0D6EF4B7EQ37814208-6B36F9DE-A6F0-4B27-B900-B3629C8D0215Q37869151-6A6BFE06-E7FC-4103-A686-55369DC8275DQ39284797-A70A79EF-8755-43DD-AAFA-1FC31EA2300FQ45072965-208D843A-DC58-4668-BE51-55B6B86B9DCBQ48336668-DF5FC731-6CD3-46C4-834A-26FFF45A2EFBQ56454451-83EAD141-4DDB-4D46-B428-C76C7C06FC2F
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Monoclonal antibodies for brain tumour treatment.
@ast
Monoclonal antibodies for brain tumour treatment.
@en
type
label
Monoclonal antibodies for brain tumour treatment.
@ast
Monoclonal antibodies for brain tumour treatment.
@en
prefLabel
Monoclonal antibodies for brain tumour treatment.
@ast
Monoclonal antibodies for brain tumour treatment.
@en
P2093
P2860
P1476
Monoclonal antibodies for brain tumour treatment.
@en
P2093
Abraham Boskovitz
Carol J Wikstrand
Chien-Tsun Kuan
Michael R Zalutsky
P2860
P304
P356
10.1517/14712598.4.9.1453
P407
P577
2004-09-01T00:00:00Z